Fennec Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Fennec Pharmaceuticals's estimated annual revenue is currently $3.5M per year.
- Fennec Pharmaceuticals's estimated revenue per employee is $100,500
Employee Data
- Fennec Pharmaceuticals has 35 Employees.
- Fennec Pharmaceuticals grew their employee count by -3% last year.
Fennec Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.5M | 35 | -3% | N/A | N/A |
What Is Fennec Pharmaceuticals?
Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity in many patients, leaving many survivors of childhood cancer with permanent and irreversible hearing loss. Permanent hearing loss, even minimal, acquired at a young age has a devastating impact on development, education, and socialization and a lifelong negative impact on Quality of Life. There are no currently approved treatments for the prevention of platinum-induced hearing loss. At Fennec Pharmaceuticals, we are dedicated to the development of our investigational agent, PEDMARK™, for the prevention of ototoxicity in children, and we hope that this will enable more children to retain their hearing. In honor of our namesake, the fennec fox, we strive to embody adaptability and resourcefulness in everything we do. Please see www.fennecpharma.com for more information.
keywords:N/A
N/A
Total Funding
35
Number of Employees
$3.5M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Research Triangle Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.9M | 35 | 30% | N/A |
#2 | $9.5M | 38 | 9% | N/A |
#3 | $11.9M | 42 | -5% | N/A |
#4 | $5.2M | 45 | 2% | N/A |
#5 | $11.9M | 53 | 6% | N/A |